Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

Shares of Dyne Therapeutics, Inc. (DYN) , a clinical-stage muscle disease company, tumbled 30.7% on two key announcements. The company announced that some of its senior executives have stepped down from their respective positions. Earlier, DYN reported mixed data from its ongoing phase I/II study, the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD). Year to date, Dyne has surged 155.8% against the industry's 2.9% decline. Image Source: Zacks Investment Research Dyne Reports New ...